Transgene Stock

TNG

FR0005175080

Biotechnology & Medical Research

Market Closed - Euronext Paris 11:55:00 2026-10-22 am EDT			5-day change	1st Jan Change
0.6800 ^EUR	+0.29%		-1.45%	-29.17%

Sep. 25	Transgene provides update on its operations
Sep. 08	Transgene Expands ProBioGen Partnership With Additional License	MT

Last Transcript: Transgene

Transgene SA - Special Call

Jun. 29

More transcripts

Analysts' recommendations: Transgene

Jun. 25	Oddo BHF Stays Positive on Transgene
Apr. 07	Transgene stands out following licensing agreement with NEC Bio
Nov. 27	Oddo BHF Lowers Target Price on Transgene but Remains Upbeat
25-10-13	Transgene and BioInvent International AB Jointly Present a Poster on Transational Data and Updated Clinical Results from the Phase I Study of BT-001	CI
25-09-18	Transgene: analysts reiterate their recommendations after results

More recommendations

News in other languages: Transgene

Oct. 05	Transgene présentera des données précliniques sur PoxSTG-EEV
Oct. 05	Transgene présentera un poster sur les données précliniques de son virus oncolytique innovant au SITC 2026
Oct. 01	Transgene participera à l’Investor Access
Sep. 25	Bourse : les Arnault à la Maison Blanche, HelloFresh avertit et Meta 2000
Sep. 25	Transgene fait le point sur son activité

More news

Managers and Directors: Transgene

Manager	Title	Age	Since
Alessandro Riva CEO	Chief Executive Officer	65	2023-05-31
Lucie Larguier DFI	Director of Finance/CFO	-	2024-03-26
Simone Steiner CTO	Chief Tech/Sci/R&D Officer	-	2025-04-01

Director	Title	Age	Since
Benoît Habert BRD	Director/Board Member	61	2010-07-26
Jean-Luc Bélingard BRD	Director/Board Member	77	2013-06-18
Alain Mérieux BRD	Director/Board Member	88	2006-12-31

More insiders

Transgene is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 4 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene has a production site in France.

Employees

152

Sector

Biotechnology & Medical Research

Calendar

Nov. 08 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-10-22	€0.6800	+0.29%	20,310
26-10-21	€0.6780	-0.59%	37,617
26-10-20	€0.6820	-0.15%	37,729
26-10-19	€0.6830	-0.73%	53,566
26-10-16	€0.6880	+0.88%	46,787

Real-time Euronext Paris

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.6780EUR

Average target price

1.100EUR

Spread / Average Target

+62.24%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Transgene

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Transgene

Company calendar

Market Cap	186M 208M 171M 156M 292M 19.71B 296M 2.06B 813M 10.32B 781M 764M 32.71B	P/E 2026 *	-4.84x	P/E 2027 *	-3.08x
Enterprise Value	116M 131M 107M 97.64M 183M 12.36B 186M 1.29B 510M 6.48B 490M 479M 20.52B	EV / Sales 2026 *	16.2x	EV / Sales 2027 *	24.7x
Free-Float	19.11%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	TNG	Real-time
Börse Stuttgart	TGNA	Delayed
CBOE	TNGp	Real-time
OTC Markets	TRGNF	Delayed
Deutsche Boerse AG	TGNA	Delayed
CBOE	0OCQ	Real-time
Boerse Muenchen	TGNA	Real-time

Sep. 25	Transgene provides update on its operations
Sep. 08	Transgene Expands ProBioGen Partnership With Additional License	MT
Sep. 03	Transgene jumps 20% on positive cancer vaccine data in early trial	RE
Sep. 02	Transgene: no cases of recurrence at three years among patients treated with TG4050
Sep. 02	Transgene And NEC Corporation Report 100% Three-Year Disease-Free Survival With TG4050 And Publish Phase 1 Results In Nature Communications	CI
Jun. 29	Transgene SA - Special Call
Jun. 25	Oddo BHF Stays Positive on Transgene
Jun. 25	Positive Preclinical Data for a Transgene Vaccine
Jun. 25	Transgene Presents Preclinical Data Demonstrating Robust Protection Against Mpox With Its Novel Scalable Cell Line?Derived MVA Vaccine Candidate TG-MVATM	CI
Jun. 22	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	CI
Jun. 22	Transgene launches a clinical trial evaluating TG4070 with nivolumab
Jun. 22	Transgene Begins Phase 1 Trial of Non-small Cell Lung Cancer Vaccine	MT
May. 22	Transgene SA Announces Board Appointments	CI

Oct. 05	Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026	GL
Oct. 01	Transgene to Participate in Investor Access	GL
Oct. 01	Transgene to Participate in Investor Access	AQ
Sep. 24	Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field	GL
Sep. 24	2026 Half-Year Financial Report	GL

1 day	+0.29%
1 week	-1.45%
Current month	-5.82%
1 month	-20.47%
3 months	-7.10%
6 months	-10.53%
Current year	-29.17%

Transgene Stock

Stocks

TNG

FR0005175080

Biotechnology & Medical Research

Valuation: Transgene

Chart: Transgene

Latest news: Transgene

Last Transcript: Transgene

Analysts' recommendations: Transgene

Press Releases: Transgene

News in other languages: Transgene

Quotes and Performance

Price Extremes

Managers and Directors: Transgene

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

1 week	0.67	0.7
1 month	0.67	0.86
Current year	0.67	1.03
1 year	0.67	1.5
3 years	0.53	1.54
5 years	0.53	2.99
10 years	0.53	3.79

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/2/25	Compagnie Merieux Alliance SAS	Buy	Company	84,745,400	63.8367%
12/2/25	Compagnie Merieux Alliance SAS	Buy	Company	38,492,172	28.9953%
8/2/24	Compagnie Merieux Alliance SAS	Buy	Company	30,898,876	23.3562%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRANSGENE	+0.29%	-1.45%	-49.82%	-50.94%	208M
WUXI APPTEC CO., LTD.	-4.10%	-8.35%	+38.48%	+66.99%	66.22B
ARGENX SE	-0.41%	+4.99%	+7.61%	+72.82%	55.2B
LONZA GROUP AG	+0.74%	+7.31%	+12.50%	+88.71%	52.79B
IQVIA HOLDINGS INC.	+0.61%	+2.69%	+27.75%	+51.50%	45.53B
BEONE MEDICINES AG	-1.08%	+2.19%	+21.92%	+126.56%	43.94B
REVOLUTION MEDICINES, INC.	-3.39%	-0.83%	+254.27%	+922.56%	41.64B
CELLTRION, INC.	-1.67%	+8.06%	+14.17%	+56.67%	34B
WUXI BIOLOGICS (CAYMAN) INC.	-8.38%	-9.01%	+25.65%	-1.82%	25.84B
GENMAB A/S	+1.30%	+6.97%	+38.37%	+28.59%	23.51B
Average	-1.58%	+2.91%	+39.09%	+136.16%	38.89B
Weighted average by Cap.	-1.65%	+3.43%	+47.52%	+159.44%

	2026 *	2027 *
Net sales	7.2M 8.07M 6.64M 6.03M 11.32M 764M 11.5M 80.02M 31.52M 400M 30.28M 29.63M 1.27B	7.2M 8.07M 6.64M 6.03M 11.32M 764M 11.5M 80.02M 31.52M 400M 30.28M 29.63M 1.27B
Net income	-38.2M -42.8M -35.24M -32.02M -60.07M -4.05B -60.99M -425M -167M -2.12B -161M -157M -6.73B	-61.6M -69.01M -56.83M -51.63M -96.86M -6.54B -98.35M -685M -270M -3.42B -259M -253M -10.85B
Net Debt	-69.2M -77.53M -63.84M -58M -109M -7.34B -110M -769M -303M -3.85B -291M -285M -12.19B	-7.7M -8.63M -7.1M -6.45M -12.11M -817M -12.29M -85.58M -33.71M -428M -32.38M -31.69M -1.36B